SRPT - Sarepta Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Cambridge,
United States
Type: Equity
SRPT price evolution
SRPT
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $383.62 | $427.29 | $428.43 | |
| Short term investments | $1076.85 | $963.45 | $1247.82 | |
| Net receivables | $515.99 | $360 | $378.81 | $400.33 |
| Inventory | $565.92 | $690.49 | $581.07 | $514.23 |
| Total current assets | $2685.37 | $2683.64 | $2464.86 | $2579.33 |
| Long term investments | ||||
| Property, plant & equipment | $446.69 | $400.2 | $375.57 | $357.11 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $740.62 | $759.52 | $685.25 | |
| Total investments | $1076.85 | $963.45 | $1247.82 | |
| Total assets | $3599.93 | $3424.26 | $3224.39 | $3264.58 |
| Current liabilities | ||||
| Accounts payable | $118.77 | $107.42 | $91.54 | $164.92 |
| Deferred revenue | $447.04 | $437 | $487.42 | |
| Short long term debt | $91.5 | $105.59 | $123.33 | |
| Total current liabilities | $699.49 | $688.49 | $608.71 | $653.66 |
| Long term debt | $1135.96 | $1278.41 | $1273.76 | $1273.48 |
| Total noncurrent liabilities | $1658.7 | $1654.48 | $1751.58 | |
| Total debt | $1369.92 | $1379.35 | $1396.81 | |
| Total liabilities | $2378.86 | $2347.19 | $2263.19 | $2405.24 |
| Shareholders' equity | ||||
| Retained earnings | -$4370.02 | -$4403.63 | -$4410.09 | -$4446.21 |
| Other shareholder equity | $2.25 | -$1.03 | -$0.69 | $0.92 |
| Total shareholder equity | $1077.07 | $961.19 | $859.34 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $428.43 | $966.78 | $2115.87 | $1502.65 |
| Short term investments | $1247.82 | $1022.6 | $435.92 | |
| Net receivables | $400.33 | $259.7 | $152.99 | $101.34 |
| Inventory | $514.23 | $203.97 | $186.21 | $231.96 |
| Total current assets | $2579.33 | $2557.86 | $2604.1 | $2485.2 |
| Long term investments | ||||
| Property, plant & equipment | $357.11 | $244.99 | $236.69 | $282.19 |
| Goodwill & intangible assets | $7.58 | $14.24 | $13.63 | |
| Total noncurrent assets | $685.25 | $570.5 | $543.88 | $499.52 |
| Total investments | $1247.82 | $1022.6 | $435.92 | |
| Total assets | $3264.58 | $3128.37 | $3147.97 | $2984.72 |
| Current liabilities | ||||
| Accounts payable | $164.92 | $95.88 | $76.74 | $111.09 |
| Deferred revenue | $487.42 | $574.24 | $663.49 | $752.73 |
| Short long term debt | $123.33 | |||
| Total current liabilities | $653.66 | $619.6 | $452.73 | $416.03 |
| Long term debt | $1273.48 | $1544.29 | $1138.39 | $1072.86 |
| Total noncurrent liabilities | $1751.58 | $2123.81 | $1767.23 | $1806.93 |
| Total debt | $1396.81 | $1601.87 | $1138.39 | $1072.86 |
| Total liabilities | $2405.24 | $2743.42 | $2219.97 | $2222.96 |
| Shareholders' equity | ||||
| Retained earnings | -$4446.21 | -$3910.24 | -$3206.75 | -$2848.13 |
| Other shareholder equity | $0.92 | -$1.66 | -$0.02 | $0 |
| Total shareholder equity | $859.34 | $384.95 | $928.01 | $761.76 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $467.17 | $362.93 | $413.46 | $396.78 |
| Cost of revenue | $44.55 | $50.56 | $44.18 | |
| Gross Profit | $375.48 | $318.39 | $362.9 | $352.61 |
| Operating activities | ||||
| Research & development | $179.69 | $200.4 | $195.52 | |
| Selling, general & administrative | $138.8 | $127 | $131.7 | |
| Total operating expenses | $353.28 | $319.09 | $328 | $327.98 |
| Operating income | -$0.7 | $34.91 | $24.63 | |
| Income from continuing operations | ||||
| EBIT | $13.58 | $41.45 | $40.37 | |
| Income tax expense | $0.4 | $7.12 | $5.33 | -$5.28 |
| Interest expense | $4.2 | |||
| Net income | ||||
| Net income | $33.61 | $6.46 | $36.12 | $45.66 |
| Income (for common shares) | $6.46 | $36.12 | $45.66 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1243.34 | $933.01 | $701.89 | $540.1 |
| Cost of revenue | $150.34 | $139.99 | $97.05 | $63.38 |
| Gross Profit | $1092.99 | $793.02 | $604.84 | $476.72 |
| Operating activities | ||||
| Research & development | $877.39 | $877.09 | $771.18 | $722.34 |
| Selling, general & administrative | $481.87 | $451.42 | $282.66 | $317.88 |
| Total operating expenses | $1360.82 | $1329.22 | $1064.55 | $1040.88 |
| Operating income | -$267.82 | -$536.2 | -$459.71 | -$564.16 |
| Income from continuing operations | ||||
| EBIT | -$520.1 | -$689.96 | -$418.95 | -$553.07 |
| Income tax expense | $15.88 | $13.53 | -$0.17 | $1.06 |
| Interest expense | ||||
| Net income | ||||
| Net income | -$535.98 | -$703.49 | -$418.78 | -$554.13 |
| Income (for common shares) | -$535.98 | -$703.49 | -$418.78 | -$554.13 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | $6.46 | $36.12 | $45.66 | |
| Operating activities | ||||
| Depreciation | $12.73 | $12.7 | $15.23 | |
| Business acquisitions & disposals | -$4 | |||
| Stock-based compensation | $50.48 | $40.69 | $45.83 | |
| Total cash flows from operations | $14.94 | -$242.08 | -$54.66 | |
| Investing activities | ||||
| Capital expenditures | -$29.17 | -$32.44 | -$19.04 | |
| Investments | -$69.36 | $261.24 | -$41.32 | |
| Total cash flows from investing | -$8.56 | -$98.53 | $218.8 | -$64.36 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $39.92 | $22.14 | $1.94 | |
| Net borrowings | ||||
| Total cash flows from financing | $75.81 | $39.92 | $22.14 | $1.94 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$230.58 | -$43.67 | -$1.14 | -$117.07 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$535.98 | -$703.49 | -$418.78 | -$554.13 |
| Operating activities | ||||
| Depreciation | $58.89 | $54.6 | $49.34 | $39.74 |
| Business acquisitions & disposals | $98 | $102 | $108.07 | |
| Stock-based compensation | $182.51 | $233.02 | $113.94 | $108.07 |
| Total cash flows from operations | -$500.99 | -$325.35 | -$443.17 | $107.47 |
| Investing activities | ||||
| Capital expenditures | -$76.11 | -$30.82 | -$38.49 | -$82.2 |
| Investments | -$176.46 | -$1013.63 | $436.01 | -$144.09 |
| Total cash flows from investing | -$165.8 | -$1046.88 | $495.41 | -$121.72 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $51.25 | $30.04 | $569.33 | $396.01 |
| Net borrowings | $303.45 | $291.11 | ||
| Total cash flows from financing | $125 | $232.51 | $561.57 | $682.32 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$541.79 | -$1139.72 | $613.81 | $668.07 |
News
Fundamentals
| Market cap | $4.80B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 95.49M |
| Revenue | $1.64B |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | $121.84M |
| Revenue Q/Q | 40.79% |
| Revenue Y/Y | 48.45% |
| P/E ratio | 39.43 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 2.93 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | $1.28 |
|---|---|
| ROA | 3.61% |
| ROE | N/A |
| Debt/Equity | 2.80 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 3.84 |
| Quick ratio | 3.03 |